Trial reportBreast cancer research and treatment2018
Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927).
Trial report in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- The Effects of Omega-3 Polyunsaturated Fatty Acids on Breast Cancer as a Preventive Measure or as an Adjunct to Conventional Treatments.Nutrients · 2023Pooled it
- Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.The Cochrane database of systematic reviews · 2022Pooled it
- Trial
- Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial.Breast cancer research and treatment · 2024Trial
- Comparison of Acupuncture vs Sham Acupuncture or Waiting List Control in the Treatment of Aromatase Inhibitor-Related Joint Pain: A Randomized Clinical Trial.JAMA network open · 2022Trial
- Yoga versus massage in the treatment of aromatase inhibitor-associated knee joint pain in breast cancer survivors: a randomized controlled trial.Scientific reports · 2021Trial
- A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Trial
- Trial
- A Randomized Controlled Trial of Hypnosis to Manage Musculoskeletal Pain in Breast Cancer Survivors Taking Aromatase Inhibitors.Psychology of consciousness (Washington, D.C.) · 2025Article
- Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer: Insights into Toxicities and Their Management.Cancers · 2025Review
- Current Evidence on the Impact of Diet, Food, and Supplement Intake on Breast Cancer Health Outcomes in Patients Undergoing Endocrine Therapy.Nutrients · 2025Review
- Precision pharmacology in menopause: advances, challenges, and future innovations for personalized management.Frontiers in reproductive health · 2025Review
- Current and future advances in practice: aromatase inhibitor-induced arthralgia.Rheumatology advances in practice · 2024Review
- New Insights into Prospective Health Potential of ω-3 PUFAs.Current nutrition reports · 2023Review
- The effectiveness of omega-3 fatty acids on health outcomes in women with breast cancer: A systematic review.Food science & nutrition · 2023Review
- Causal association of polyunsaturated fatty acids with chronic pain: a two-sample Mendelian randomization study.Frontiers in nutrition · 2023Article
- A Narrative Review of the Safety of Anti-COVID-19 Nutraceuticals for Patients with Cancer.Cancers · 2021Review
- Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor-Associated Musculoskeletal Symptoms.JNCI cancer spectrum · 2021Article
- Managing Common Estrogen Deprivation Side Effects in HR+ Breast Cancer: an Evidence-Based Review.Current oncology reports · 2021Review
- Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 8 institutions in 1 country.
Funding
Abstract
purposeAlthough aromatase inhibitors (AIs) prolong survival in post-menopausal breast cancer (BC) patients, AI-associated arthralgia can lead to discontinuation. Obese patients have higher rates of AI arthralgia than non-obese patients, but treatment options are limited. Omega-3 fatty acid (O3-FA) treatment for AI arthralgia has produced mixed results.
methodsWe performed an exploratory analysis of SWOG S0927, a multicenter randomized placebo-controlled trial of O3-FA use for AI arthralgia. Post-menopausal women with stage I-III BC taking an AI were randomized to 24 weeks of O3-FAs or placebo. Brief Pain Inventory (BPI) questionnaires and fasting serum were collected at baseline, 12, and 24 weeks. The BPI assessment included worst pain, average pain, and pain interference scores (range 0-10).
resultsAmong the 249 participants, 139 had BMI < 30 kg/m
conclusionsIn obese BC patients, O3-FA use was associated with significantly reduced AI arthralgia compared to placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.